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Foams have frequently been used as systems for the delivery of
cosmetic and therapeutic molecules; however, there is high
variability in the foamability and long-term stability of synthetic
foams. The development of pharmaceutical foams that exhibit
desirable foaming properties, delivering appropriate amounts of
the active pharmaceutical ingredient (API) and that have
excellent biocompatibility is of great interest. The production of
stable foams is rare in the natural world; however, certain
species of frogs have adopted foam production as a means of
providing a protective environment for their eggs and larvae
from predators and parasites, to prevent desiccation, to control
gaseous exchange, to buffer temperature extremes, and to
reduce UV damage. These foams show great stability (up to 10
days in tropical environments) and are highly biocompatible
due to the sensitive nature of amphibian skin. This work
demonstrates for the first time that nests of the túngara frog
(Engystomops pustulosus) are stable ex situ with useful
physiochemical and biocompatible properties and are capable
of encapsulating a range of compounds, including antibiotics.
These protein foam mixtures share some properties with
pharmaceutical foams and may find utility in a range of











































Foams have been used as delivery systems or vehicles to deliver cosmetic and therapeutic molecules to normal
and injured skin since the 1970s [1–5]. Yet the long-term stability of liquid aqueous foams has been a challenge,
with some formulations offeringuseful foamability properties (e.g. foamexpansion time), but poor stability [6].
There has been some progress made through the combination of various foam and surfactant components to
create high foamability and long-term foam stability [6–9].However, thedevelopment of biocompatible, liquid
foams with high foamability and long-term stability remains a challenge in materials science [6]. A range of
foams is already in use for topical treatments, such as Ibuprofen foams (Biatain® Ib) used to relieve a wide
range of exuding wounds, urea-containing foams (KerraFoam) to help alleviate the symptoms of psoriasis,
and antibiotic foams containing clindamycin and other antimicrobials such as silver sulfacetamide [2,4]. A
major advantage of medicated foams is their ability to cover large surface areas, while containing highly
concentrated drugs for topical treatment [1]. One major difficulty can be the delivery of an adequate
concentration of active pharmaceutical ingredients (APIs) for treatment over a sustained period, therefore
often necessitating repeated, regular applications. In the case of open wounds and burns, regular removal
of dressings may lead to increased infection risk and damage to healing surfaces, aid the emergence of
antimicrobial resistance through the delivery of sub-minimum inhibitory concentrations of antibiotics,
ultimately resulting in reduced infection control and wound healing [10]. Liposomes have been proposed
for dermatological applications; however, they exhibit major stability issues. There is therefore a need for
the development of biomaterials that allow extended times between application combined with high
stability and improved biocompatibility; natural foams can provide these benefits.
Anurans (frogs) exhibit anenormousdiversity in reproductive strategies andstyles [11], andmanyspeciesof
tropical and subtropical frog lay their eggs in stable proteinaceous foams that differ in composition between
species. Foam-nesting behaviours, thought to have evolved as a means to avoid aquatic predators, prevent
desiccation of eggs, control gaseous exchange, buffer temperature extremes, reduce solar radiation damage
and protect eggs from microbial colonization [12]. Stable biological foams and foam-producing surfactants
are rare in nature, presumably due to the requirement for high-energy input for their generation, and the
potential of surface-active components to negatively affect cell and membrane function [13,14]. Frog nest
foams are remarkable for their strong surfactant activity combined with harmlessness to naked eggs and
sperm. The leptodactylid frogs of the neotropics are one such anuran lineage that has evolved stable foams
as an offspring protection mechanism. The nests of the túngara frog (Engystomops pustulosus) are remarkable
in structures that act as incubation chambers for eggs [15] (electronic supplementary material, figure S1a
and b), allowing rapid growth and development of embryos, offering a protective environment against
predation, while providing temperature regulation and oxygen transfer for optimal growth conditions. These
nests are not destroyed by microbes during larval development despite construction within highly microbe-
rich water [16]. The foam nest structure is highly stable, remaining assembled for as much as 10 days in the
tropical environment [17,18], yet the surfactant activity of the foam does not cause damage to the sperm,
eggs or developing embryos [13]. The main surfactant protein within these nests is an 11 kDa protein,
Ranaspumin-2 (RSN-2), which does not disrupt biological membranes or cells, but it still provides sufficient
surfactant activity in the air–water interface to allow foam formation [19]. The RSN-2 protein appears to
form a clamshell-like structure, which can undergo an unfolding conformational change to expose non-polar
patches on the protein surface to the air, while highly polar regions remain in contact with the water interface
to provide the surfactant activity. RSN-2 has been successfully used in industry as a surfactant in
nanoparticle production [20], but there could be great potential for the whole nest foam protein composition
to be used in a range of pharmaceutical applications.
Here we show that the unseparated, total protein mixture of E. pustulosus nest foam is stable ex situ for
extended periods with useful physiochemical and biocompatible properties, does not need the addition
of oxygen as with other drug delivery systems ([21]; DDS) and may be used to encapsulate a range of
hydrophobic and hydrophilic model compounds. These data suggest that anuran-derived protein
foams may have broad potential applications in pharmaceutics and as DDSs.2. Results and discussion
2.1. Biophysical properties of túngara frog foam preparation
The composition and properties of DDSs can determine the effectiveness of drug release, and while
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Figure 1. Structural characterization of E. pustulosus nest foam proteins. (a) Circular dichroism of foam fluid using 0.1 mm
path length cuvettes containing 1 mg ml−1 protein foam fluid solution. (b) FTIR foam fluid and (c) whole foam. For both CD
and FTIR, spectra were corrected for baseline and buffer effects, each measurement was carried out in triplicate, and the mean









































key [22]. Thus, increasing and stabilizing the local concentration of the permeant is the simplest strategy
to facilitate bioavailability [3]. The protein composition of E. pustulosus foam fluid was analysed by
sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE) (electronic supplementary
material, figure S1c), confirming previous work that foam from this species contains six major
proteins ranging between 10 and 40 kDa in size [18] and that the foam nests used in this study were
of typical composition. We observed no variation between collection years or from nests collected at
different locations in Trinidad and all foam collected was checked by SDS-PAGE and was of the
composition previously detailed in [17–19] and electronic supplementary material, figure S1c.
Dichroism spectroscopy (CD) spectra of the samples showed a negative maximum at 215 nm and a
positive maximum at 194 nm, (figure 1a) indicating that, cumulatively, the protein mixture in the foam
fluid comprises predominately β-sheet structures. Further insight into the secondary structure of the
foam mixture was obtained by Fourier transform infrared (FTIR), which also exhibited spectra





































Figure 2. Viscoelastic properties of E. pustulosus nest foam. (a) Time sweep rheology data for foam, showing both elastic (G0) and
viscous (G00) moduli. Stress was set at 100 Pa and carried out over 1 h. (b) Oscillation sweep rheology data for E. pustulosus foam,










































transitions were observed at approximately 1680 cm−1, which are frequencies characteristic of Amide I
band, signifying C=O bond stretches typically engaged in β-sheet bonded network structures. These
data support previous observations that the average secondary structure content of the proteins is
predominantly β-sheet [18] and indicates that the centrifugation steps in the preparation of the foam
for these experiments does not alter the overall structure and composition of the foam from the wild
E. pustulosus nests.
To investigate the viscoelastic properties of the foam, oscillation sweep experiments were employed
by rheology. The whole foam fluid was found to tolerate up to 100 Pa of shear stress force before it
reaches a breaking point, at which the elastic modulus of the foam decreases and foam structure and
stability is lost (figure 2a). Time sweep experiments indicated that up to 1500 s the foam preparation
moduli are unchanged by stress and frequency. After 1500 s, both elastic and viscosity moduli
increase, demonstrating that water is being lost from the foam (figure 2b). It has been suggested that
stress increases the chances of water loss from the foam followed by coarsening, which leads to an
increase in viscoelasticity [24]. The E. pustulosus whole foam is able to withstand shear stress and
pressure before breaking down, demonstrating the long-lasting stability that may be observed in
nature. Pharmaceutical foams are typically required to remain stable in order to be properly
manipulated while being applied, but have low shear, allowing them to break down shortly thereafter
[25,26]. The foam derived from E. pustulosus has exhibited long-term stability in harsh tropical
environments (e.g. heat, high-level exposure to ultraviolet light and physical disruption) and behaves
differently from typical pharmaceutical foams [2]. The E. pustulosus foam is stable enough to be













































Figure 3. Biocompatibility of E. pustulosus nest foam with human epithelial cells. MTT assay of HaCaT cell percentage viability
following exposure to a range of fluid foam concentrations over 24 h at 37°C. Each treatment was performed in triplicate, and
media alone was used as normal viability control (100%), and cells were treated with DMSO for non-viable control. Treatments
were a dilution of fluid foam protein concentrations −1.4, 0.3, 0.14 and 0.07 mg ml−1, respectively. Error bars represent the









































2.2. Frog foam biocompatibility with human epithelial cells
To investigate the susceptibility of mammalian cells to any possible toxic effects of the foam, cells were
cultured in the presence of foam fluid, and potential toxicity was assayed using an MTT-based cell
viability assay. Exposing HaCaT keratinocyte cells to a range of E. pustulosus foam concentrations did
not affect the overall cell viability and multiplication of the cells (figure 3). The higher foam fluid
concentrations to which the cells were exposed are representative of foam concentration present in
E. pustulosus nests (1–2 mg ml−1 protein [17]). Cells exposed to the foam behave in the same manner
as untreated control cells, demonstrating that the foam proteins from E. pustulosus are non-toxic to
epithelial cells and are therefore unlikely to cause damage to the skin or underlying tissues if used as
a topical DDS. The foam and its protein components are already known to be harmless to human
erythrocytes [27]. This high degree of biocompatibility is consistent with the foam and its precursor
components being harmless to naked amphibian sperm, eggs and oviduct surfaces of the frogs [27].2.3. In vitro release of drug-loaded frog foam
A single foam cell is defined as a bubble of gas enclosed in a liquid film that can be polyhedral or circular,
heterogeneous or homogeneous, and usually ranges between 0.1 and 3 mm in diameter [25]. The cell
structure of E. pustulosus nest foam was evaluated microscopically and the foam cell sizes measured
(figure 4a). The foam cells in all samples were found to be a heterogeneous mixture of uneven,
spherical and polyhedral cells with a Feret diameter ranging from 10 to 800 µm, falling in the normal
range of foam cell size of foams that have been used previously in pharmaceutical applications [25].
The relative density of the foamwas found to be 0.25 g of proteinml−1. Atomic forcemicroscopy (AFM)
PeakForce analysis of the fluid foam and gel foam indicated consistency of the individual adhesion force
(Fad) measurements in each foam form (figure 4b), indicating that the foam surface forces are homogeneous
across the surface of each form. Moreover, in the case of the fluid foam, the Fad is higher and the AFM
images show the formation of approximately 200 nm droplets as the foam was dried on to mica
surfaces. This combination of low density and high structural stability is unusual and suggests anuran
foam nest proteins exhibit similar properties to pharmaceutical foams.
To evaluate the drug release behaviour of E. pustulosus foam, experiments were performed using a
dialysis-based method where two model compounds (one hydrophobic and one hydrophilic), Nile red
(NR) and calcein, were encapsulated in the foams. Calcein exhibits a ‘burst-type’ release profile from
the foam, whereas NR is discharged at a linear rate over 7 days (168 h; figure 5a,b). These data
indicate that the whole foam can absorb and release both hydrophobic (NR) and hydrophilic (calcein)
molecules and release these at different rates over a prolonged period, with up to 85% of the loaded
dye released up to 7 days (168 h). Longer time periods were not studied, as typically release of APIs
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Figure 4. Drug loading of E. pustulosus nest foam does not alter the structure of the foam. (a) Foam cell diameter measurements
scatter plot. Feret diameter of each foam cell/bubble was measured using Fiji software. Bars on the scatter encompass 10–90% of the
data points, with the central horizontal line representing mean values. Above the scatter graph are representative images of unloaded
foam, foam loaded with 1 mg ml−1 Nile red (NR) and foam loaded with 1 mg ml−1 calcein. All images were taken using freshly










































the foam in the natural environment [15]. Moreover, the loading of the nest foam with NR or calcein did
not alter the cell size or shape of the foam (figure 4). The unique release properties associated with the E.
pustulosus foam may in part be explained by the unique surfactant properties and ‘clam shell’ structure
adopted by at least one member of the protein complex in solution. RSN-2 is an amphiphilic polypeptide
which exhibits no obvious hydrophobic patches or structural features that are normally associated with
surfactant proteins [14]. RSN-2 is able to adopt an open ‘clam-shell’ configuration to present the
hydrophobic faces of the protein to the interface while maintaining contact of the polar regions of the
protein with the aqueous phase. This may enable the E. pustulosus foam proteins to modify their
structure according to the nature of the drug molecule that is loaded, resulting in the different release
profiles for hydrophobic or hydrophilic drug mimics we observed. This property is likely to broaden
their potential application as a DDS allowing E. pustulosus foam to be loaded with a range of APIs.
To test the ability of the foam to release a clinically relevant drug molecule, the whole foam was
loaded in the same manner as for the previous two molecules with the red-pigmented, polyketide
antibiotic rifampicin. Polyketide antibiotics have successfully been delivered using foam DDSs, thus
rifampicin offers a potentially useful comparison with existing systems [2] and is amenable to
spectroscopic analysis. The dialysis method of release showed that rifampicin was released at a steady
rate over the first 5 h with a release of around 80% of loaded antibiotic, followed by a second, slower
phase of release (figure 5c).
To further investigate the release of drug molecules from E. pustulosus foam, a novel transwell-based
release assay was developed, which emulates delivery of the foam preparation across a more complex
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Figure 5. E. pustulosus nest foam can take up and release model compounds and drug molecules. (a) Cumulative release of the dye
NR from loaded whole foam over 168 h using the dialysis method. (b) Cumulative release of the dye calcein from loaded whole
foam over 168 h using the dialysis method. (c) Cumulative release of the antibiotic rifampicin from loaded whole foam over 168 h
using the dialysis method; circle, concentration (mg ml−1); grey square, percentage release of the dye or drug. (d ) Release of
rifampicin using novel transwell method; black square, concentration (mg ml−1 of protein); blue square, percentage release of
rifampicin. Each point represents the mean of data collected in triplicate and error bars indicate the standard deviation of the
data. Sink conditions were satisfied by replacing sample volume with fresh buffer at each sample point. Dye release
concentrations were calculated using spectrophotometric standard curves for respective dye or drug. (e) Schematic representing
the experimental set-up using the novel transwell release assay, with reservoirs of 24-well plate filled with buffer (i), the
insertion of the permeable transwell (ii), and the addition of drug-loaded foam to the transwell (iii) to allow drug release









































plate containing 1 ml of phosphate-buffered saline (PBS), and release of drug molecule was determined
through the assay of the amount of rifampicin that passed from the foam through the transwell membrane.
In the transwell assay, around 50% of rifampicin was also released over 48 h (figure 5d).
This novel transwell assay for investigating compound release from foams offers a simpler route to
assaying drug release from foams and other aqueous-based materials that do not require the









































a single face of the transwell (a schematic of the transwell-based assay is provided in figure 5e) with the
advantage that transwells are available in a number of sizes and pore diameters to suit a range of needs.
These data indicate that the frog foam can be loaded with drug molecules and has an extended-
release profile when compared with existing pharmaceutical foams, with release over days rather than
minutes or hours [28]. The foam from E. pustulosus is stable and the API release is relatively slow
with the foam potentially acting as a barrier in the local environment. The E. pustulosus foam also
compares well with the release of rifampicin from nanoparticles loaded with antibiotics of the same
chemical class, where 80–90% of release occurs, but within an 8 h time window [29].
Many nanoparticle-based systems release their drug load rapidly resulting in ineffective long-term
treatment possibilities [30] and have exhibited some toxic properties [31]. The anuran foam-based
preparations extend this release period to around 48 h depending on the nature of the compounds used,
expanding the possible applications of frog foams. While there have been multiple antibiotic-loaded
liposomes [32–34] (AmBisome, Lambin, Doxil) brought to market, little have transferred the
applicability to topical conditions, and their efficiency is still lacking. Further, tetracycline (a polyketide
antibiotic) loaded nanocomposite hydrogels that have been used for extended-release delivery through
the skin, released a maximum of 15% of their antibiotic load [33]. Foams are considered more popular
with patients than gels [2], and a stable foam may provide a solution to both of these issues. Previous
studies of pharmaceutical foams have investigated the immediate delivery of drugs through to the
dermis by exploiting the fast breakdown of foam preparations, but rarely have they been used for long-
term drug release [2]. The foam derived from E. pustulosus provides a material with potential due to its
intermediate release properties; where API uptake is efficient, it has high stability and the slow release
properties enable continuous release over a clinically useful period of time.3. Conclusion
There is an increased interest in DDS to refine the use of antimicrobial drugs currently available on the
market, which may enable novel delivery systems to help combat the rise of antimicrobial resistance in
the clinic. Anuran foams from reproductive nests may provide a novel area for future investigation in
controlled release. Anuran foam nests share properties with pharmaceutical foams, they are highly
biocompatible, durable and stable, and have excellent drug release properties. They exhibit a few of
the issues associated with fabric-based drug release such as instability, rapid release characteristics or
toxicity. These advantages suggest that with further research anuran foams have potential for use as a
pharmaceutical foam. To fully meet the demands of modern pharmaceutical manufacture,
formulation, sterility, product consistency and for reasons of sustainability, it is envisaged that
heterologous production of these proteins will be required for their future exploitation in the clinic. It
has been shown that at least one protein is amenable to production in bacterial protein production
systems [19]. Further research is required to understand the interaction and properties of the six major
foam proteins in combination, and there may be potential to modify the protein mixture using a
heterologous expression, for example, simplify the composition of the foam mixture, modify stability
with different combinations of component proteins, etc. There is also potential for the use of
individual proteins from the nest protein complex as pharmaceutical ingredients given their surfactant
properties. It is known that at least one member of the E. pustulosus foam complex (RSN-2) can be
whipped to form short-lived (lasting hours rather than days before collapsing) foams that superficially
appear similar to natural foam nests [14]. These frog foam nest proteins offer a number of avenues for
exploitation in the future, but will require further research to fully exploit their potential.4. Material and methods
4.1. Materials
NR, calcein, ethanol 97% (v/v) and PBS tablets (pH 7.2) were all purchased from Sigma, and MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium was purchased from Thermofisher.
4.2. Collection of Engystomops pustulosus foam
Freshly laid foam nests or adult frogs in amplexus (allowed to lay in captivity, before release) were









































were removed from the surface of the water in which they were produced (an in situ nest can be seen in
the electronic supplementary material, figure S1b), and the eggs were removed manually before being
stored at −20°C for transfer to Glasgow, where they were stored at −80°C. Nest foam was pooled and
checked by SDS-PAGE to ensure protein integrity (electronic supplementary material, figure S1c).
Foam was freshly defrosted for all experiments with no further processing being required, as foam
maintains its integrity upon freeze/thawing. Soluble foam material (foam fluid) was produced by
centrifuging whole foam for 10 min (16 000g), providing a solution with approximately 2 mg ml−1
protein. This also yields a supernatant/pellicle residual of semi-solid compressed foam (gel foam) on
top of the foam fluid layer.
4.3. Microscopy
4.3.1. Optical microscopy
The whole foam was defrosted at room temperature before use. All foam images were taken using
transmitted light on a Nikon SMZ1500 stereomicroscope with images acquired using a DFK 33UX264
CMOS camera (The Imaging Source Europe GmbH, Germany) using NIS-Elements AR.3.2 software.
Fiji software (https://fiji.sc/) from the ImageJ (https://imagej.net) package was used for image analysis.
4.3.2. Atomic force microscopy
Samples (5 µl) of foam were deposited onto a freshly cleaved mica surface (1.5 × 1.5 cm; G250-2 Mica
sheets 25 × 25 × 0.15 mm; Agar Scientific Ltd, Essex, UK) and left to dry at room temperature for 1 h
before imaging. The images were obtained by scanning the mica surface in air under ambient
conditions using a Scanning Probe Microscope (MultiMode® 8, Digital Instruments, Santa Barbara,
CA, USA; Bruker Nanoscope analysis software v. 1.40), operating using the PeakForce QNM mode.
The AFM measurements were obtained using ScanAsyst-air probes, for which the spring constant
(0.58 N m−1; nominal 0.4 N m−1) and deflection sensitivity had been calibrated, but not the tip radius
(the nominal value used was 2 nm).
4.4. Sodium dodecyl sulfate poly-acrylamide gel electrophoresis
Solid and liquid foam samples were electrophoresed on precast NuPAGE 15% poly-acrylamide Bis-Tris
gels (Invitrogen) at 120 V using 4 XSDS reducing loading buffer (Invitrogen). Each gel was stained with
InstaBlue Coomassie protein stain for approximately 45 min.
4.5. Circular dichroism spectroscopy
CD was used to investigate the overall secondary structure content of the proteins. Spectra were
acquired using a Chirascan Plus (Applied Photophysics) instrument using a 0.1 mm quartz cuvette
(Hellma) at 20°C. All samples (10 mg ml−1 protein) were measured in the far-UV in a wavelength range
of 180 to 280 nm, with step size of 1 nm, bandwidth of 1 nm and reading time of 1 s nm−1. Triplicate
measurements were taken for each sample run, baseline peak, PBS control and foam sample spectra,
with triplicate spectra then averaged. Baseline and PBS traces where subtracted from the sample spectra
before secondary structure predictions were made. All data analysis was performed using Global3
software and Excel.
4.6. Fourier transform infrared spectroscopy
FTIR spectroscopy was carried out using a Nicolet iS10 Smart iTR spectrophotometer (Thermo Scientific).
Solid and liquid foam spectra were recorded in the range of 4000 and 500 cm−1, over 128 scans at a
resolution of 4 cm−1 and an interval of 1 cm−1. Background spectra were measured and the foam
spectra were corrected accordingly.
4.7. Rheology
Rheology measurements were determined using a HAAKE MARS rotational rheometer (Thermo









































carried out using P20 upper plate and TM20 lower plate. The oscillation sweeps were completed with a
1 mm gap and 0.1 to 200 Pa range. Time sweep experiments were run for 1 h, at 100 Pa and 3 Hz using a
0.5 mm gap. Data points were collected in triplicate and averaged before analysis was carried out.
4.8. MTT cell viability assay
HaCaT cells (CLS, Eppelheim, Germany), a model human keratinocyte cell line, were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g l−1 glucose supplemented with 10%
(v/v) fetal bovine serum, 2 mM L-glutamine and 50 units ml−1 penicillin/streptomycin (cDMEM;
Lonza, Slough, UK). Soluble foam proteins were prepared as above, with the supernatant being
passed through the 0.22 μm filter (Millex 33 mm) and subsequently concentrated using an Amicon
10 kDa spin filter. The protein concentration was determined by Bradford assay (BioRad). The HaCaT
cells were plated onto 96-well plates (approx. 1 × 103 cells per well and grown to 80% confluence) and
were treated with buffer containing foam proteins (concentrations indicated in the figures) prior to
incubation at 37°C for 24 h. After 24 h, the media was removed from the cells and replaced with 50 µl
of fresh media and 50 µl of MTT (5 mg ml−1) and incubated for 1 h at 37°C. This was followed by
replacing the media with 100 µl DMSO and further incubation in the dark at room temperature for
30 min prior to reading the absorbance at 570 nm [35]. Results were expressed as the % cell viability
compared with non-treated cells ± s.d. of the data.
4.9. In vitro release of model compounds
Aliquots (500 mg) of whole foam were loaded with dye by mixing with either 400 µl of NR (hydrophobic;
1 mg ml−1 in ethanol) or calcein (hydrophilic; 1 mg ml−1 in ethanol). All free liquid containing NR or
calcein was encapsulated within the foam following mixing. The mixture was placed in dialysis
tubing and sealed before being submerged in 10 ml PBS at 37°C (pH 7; for NR-based release
experiments, a 1 : 1 mixture of ethanol and PBS was used). The release experiments were carried out
at 37°C, over 168 h. To satisfy the perfect-sink conditions, which allow for the determination of the
diffusion parameters, the supernatant was replaced with fresh PBS at 37°C at each time point
(indicated in the graphs). The concentration of model compound in each sample was determined
spectrophotometrically at 490 nm (calcein) or 590 nm (NR) and the concentration was determined
with reference to standard control calibration curves. Experiments were performed in triplicate.
4.10. In vitro antibiotic release
Two in vitro techniques were used to investigate the release of the antibiotic rifampicin.
4.10.1. Dialysis
Aliquots (400 mg) of foam were mixed with 400 µl of rifampicin (25 mg ml−1) as above. The loaded foam
was placed into dialysis tubing, sealed and submerged in 10 ml of PBS. This was incubated at 37°C for
48 h. Samples (1 ml) were taken and fresh media was added to maintain sink conditions. Samples where
measured spectrophotometrically at 475 nm [36] against a calibration curve.
4.10.2. Transwell
Aliquots of foam (100 mg) were mixed with 100 µl of rifampicin (25 mg ml−1). Rifampicin-loaded foam
was the placed into a transwell collagen-coated permeable support (0.4 µm; Nunc). Each support was
inserted into 24-well plate well containing 600 μl of PBS. The plate was then incubated for 48 h at
37°C. PBS (600 μl) was collected from a well for each time point, and the absorbance was measured at
475 nm, in triplicate.
Ethics. Foam nest collections were approved by the Wildlife Division of Trinidad and Tobago (Special Game Licences
2014–2016). Eggs are removed, undamaged from the foam nests and all tadpoles were returned to the nest collection
areas after foam collection. Foam nest proteins were exported under licence (Wildlife Special Export Licence nos.
001741, 001161 and 000646).
Data accessibility. All of the raw data and the electronic supplementary material, data is available on Figshare at https://
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